A few hours ago Kerastem’s CEO Mr. Brad Conlan sent me an e-mail for the first time ever. The timing of this e-mail is quite appropriate considering that I just mentioned Kerastem in my recent post related to yet another new study finding some positive correlation between adipose tissue (fat cells) and hair growth. Note that in that post, the study that I discussed entailed Kerastem’s technology (even though the UK newspaper articles that covered the development did not state so anywhere explicitly).
I am pasting Mr. Conlan’s e-mail verbatim below in blue font. Please keep discussions in the comments here civil and related to this subject matter. Unrelated comments should continue to go in my last (“brief items of interest”) post. From the first link in the below pasted e-mail, I liked the following quote from lead investigator Dr. David Perez-Meza, although it is worth keeping in mind that the study had a very small sample size of 6 patients:
“We are very pleased with the clinical outcomes of our hair regeneration study, as they represent this procedure is safe and that results are on par or better than those of traditional medical approaches to hair loss”.
I wanted to pass along that the Kerastem UK clinical study results were recently published in the Journal of Stem Cells and Cloning.
We were highly encouraged by the results of the UK study and proceeded to a 70 patient, US IDE clinical trial focused on Androgenetic Alopecia. US Clinical Trial details can be found below:
We expect to present the results from the US clinical in the Fall of 2017.